Our Mission

To reconnect humanity, Psygen will improve access to psychedelics.

We exist to support the development of psychedelic and neuroplastogen Active Pharmaceutical Ingredients (“APIs”).

Our Facility /

Psygen’s State-
of-the-Art Facility

We designed Psygen’s facility with your drug in mind. Combining our industry-leading experience in psychedelic chemistry with a dedicated facility, we are the ideal partner for psychedelic and neuroplastogen API development. Our purpose-built, 17,000-sq-ft facility includes 6,000-sq-ft of lab space for process research & development and large-scale synthesis of psychedelic and neuroplastogen APIs.

Expanding Access

As a part of Psygen’s mission to improve access to psychedelics, we have donated psychedelic drug substances to physicians through Canada’s Special Access Program, including for the first use of psilocybin through the SAP in 2022.  Psygen has also donated psychedelic APIs for humanitarian projects  around the world.

If you are operating a research or humanitarian project that requires access to LSD, MDMA, psilocybin or other psychedelics, please reach out to discuss how Psygen can support your project.

Our Impact /

Psygen
Worldwide